{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.1","upperLimit":"5.1","value":"3.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"}],"units":"Participants"}],"description":"Median PFS, measured in months from study entry to progression as defined by international response criteria or death of any cause, whichever comes first","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants receive azacitidine subcutaneously once or twice weekly and oral dexamethasone once weekly starting on day 1. Participants also receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 6 courses. Participants then continue to receive lenalidomide as maintenance therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Overall Study - (Azacitidine/Lenalidomide/Dexamethasone)"}],"paramType":"MEDIAN","populationDescription":"Evaluable participants who received treatment","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Median Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}